导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.80% | 3011/4773 |
| 近一周 | -2.31% | 1763/5462 |
| 近一月 | -3.72% | 1922/5421 |
| 近一季 | -0.31% | 800/5209 |
| 近半年 | -3.01% | 2097/4920 |
| 近一年 | -0.07% | 2659/4366 |
| 近两年 | 30.78% | 2237/2954 |
| 近三年 | 17.88% | 1553/2253 |
| 成立以来 | 172.94% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-4.28% 3586/4961 |
-0.39% 3294/5312 |
- - |
- - |
| 2025 | 11.87% 2721/4813 |
-1.88% 2805/3635 |
1.85% 2081/4076 |
9.14% 3375/4524 |
2.56% 909/4813 |
| 2024 | 17.92% 637/3463 |
3.98% 493/2808 |
0.69% 557/3014 |
15.43% 1717/3129 |
-2.42% 2076/3463 |
| 2023 | -6.30% 827/2656 |
5.54% 776/2280 |
-2.50% 602/2385 |
-1.39% 514/2515 |
-7.66% 2187/2655 |
| 2022 | -14.00% 353/2207 |
-12.53% 626/1919 |
6.59% 655/2016 |
-11.38% 529/2113 |
4.07% 596/2208 |
| 2021 | -6.37% 1007/1822 |
-0.23% 343/1255 |
-2.25% 1195/1330 |
-6.65% 974/1466 |
2.85% 506/1822 |
| 2020 | 28.70% 555/1250 |
-10.31% 771/1028 |
14.20% 566/1067 |
12.89% 355/1164 |
11.31% 552/1184 |
| 2019 | 39.23% 288/1092 |
24.37% 512/754 |
2.57% 79/804 |
1.38% 409/850 |
7.66% 412/918 |
| 2018 | -16.95% 118/834 |
- - |
- - |
- - |
-11.19% 260/691 |
| 2017 | 31.83% 48/714 |
- - |
- - |
- - |
- - |
| 2016 | 0.69% 100/605 |
- - |
- - |
- - |
- - |
| 2015 | 9.51% 163/575 |
- - |
- - |
- - |
- - |
| 2014 | 57.16% 46/237 |
- - |
- - |
- - |
- - |
| 2013 | -4.64% 90/186 |
- - |
- - |
- - |
- - |
| 2012 | 9.40% 44/140 |
- - |
- - |
- - |
- - |
| 2011 | -19.79% 36/102 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 兴全沪深300指数(LOF)A VS. 长安沪深300非周期A(740101) |